{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:59:56Z","timestamp":1792040396324,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015394","name":"American Society for Transplantation and Cellular Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.beha.2023.101470","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:30:17Z","timestamp":1681903817000},"page":"101470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens"],"prefix":"10.1016","volume":"36","author":[{"given":"Sarah A.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Grace","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-3697","authenticated-orcid":false,"given":"Jai N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.beha.2023.101470_bib1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2023.101470_bib2","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101470_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-022-00572-8","article-title":"Pharmacogenomics: current status and future perspectives","author":"Pirmohamed","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.beha.2023.101470_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-genom-111621-102737","article-title":"Advancing pharmacogenomics from single-gene to preemptive testing","volume":"23","author":"Haidar","year":"2022","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The clinical pharmacogenetics implementation consortium: 10 Years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.1641","article-title":"Prospective CYP2C19-guided voriconazole prophylaxis in patients with neutropenic acute myeloid leukemia reduces the incidence of subtherapeutic antifungal plasma concentrations","volume":"107","author":"Hicks","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cpt.1642","article-title":"Evaluation of CYP2C19 genotype-guided voriconazole prophylaxis after allogeneic hematopoietic cell transplant","volume":"107","author":"Patel","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib46","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron","volume":"102","author":"Bell","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib72","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.beha.2023.101470_bib8","unstructured":"Voriconazole [package insert], Food and Drug Administration."},{"issue":"7","key":"10.1016\/j.beha.2023.101470_bib9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.beha.2023.101470_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.beha.2023.101470_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221127503","article-title":"Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases","volume":"13","author":"Shen","year":"2022","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.030","article-title":"Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a major transplantation center","volume":"28","author":"Lindsay","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib13","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.14.53","article-title":"Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes","volume":"15","author":"Hicks","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/cpt.2233","article-title":"A novel CYP2C-haplotype associated with ultrarapid metabolism of escitalopram","volume":"110","author":"Br\u00e5ten","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.beha.2023.101470_bib19","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/cts.13347","article-title":"Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population","volume":"15","author":"Br\u00e5ten","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.beha.2023.101470_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/17425255.2021.1890715","article-title":"Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs","volume":"17","author":"Garc\u00eda-Garc\u00eda","year":"2021","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"12","key":"10.1016\/j.beha.2023.101470_bib21","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood.V85.12.3746.bloodjournal85123746","article-title":"Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study","volume":"85","author":"Nash","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2023.101470_bib22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.bmt.1702032","article-title":"Practical considerations in the use of tacrolimus for allogeneic marrow transplantation","volume":"24","author":"Przepiorka","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2023.101470_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121529","article-title":"Impact of early intrapatient variability of tacrolimus concentrations on the risk of graft-versus-host disease after allogeneic stem cell transplantation using high-dose post-transplant cyclophosphamide","volume":"15","author":"Marco","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib24","article-title":"Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from\u00a0Unrelated donors","volume":"18","author":"Moriz","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1083-8791(98)50005-5","article-title":"Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation","volume":"4","author":"Wingard","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib26","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1177\/1078155220959416","article-title":"Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation","volume":"27","author":"Soskind","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/pgs-2018-0003","article-title":"CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration","volume":"19","author":"Pasternak","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/pgs-2019-0189","article-title":"Pharmacogenetics and tacrolimus administration in stem cell transplantation","volume":"21","author":"Patel","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.bbmt.2018.12.766","article-title":"Effect of CYP3A4, CYP3A5, and ABCB1 polymorphisms on intravenous tacrolimus exposure and adverse events in adult allogeneic stem cell transplant patients","volume":"25","author":"Hamadeh","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.09.011","article-title":"Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy","volume":"28","author":"Pasternak","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030858","article-title":"Influence of germline genetics on tacrolimus pharmacokinetics and pharmacodynamics in allogeneic hematopoietic stem cell transplant patients","volume":"21","author":"Zhu","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.beha.2023.101470_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5500\/wjt.v10.i5.90","article-title":"Pharmacogenetics of immunosuppressant drugs: a new aspect for individualized therapy","volume":"10","author":"Salvadori","year":"2020","journal-title":"World J Transplant"},{"issue":"10","key":"10.1016\/j.beha.2023.101470_bib34","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s40262-021-01037-7","article-title":"The impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of mycophenolic acid: systematic review and meta-analysis","volume":"60","author":"Na Takuathung","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"10.1016\/j.beha.2023.101470_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/pgs-2022-0133","article-title":"Application of pharmacogenomics in supportive oncology: a patient journey","volume":"23","author":"Nguyen","year":"2022","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib36","first-page":"555","article-title":"Opportunities for pharmacogenomics-guided supportive care in cancer","volume":"29","author":"Patel","year":"2021","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib37","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1634\/theoncologist.2017-0599","article-title":"Value of supportive care pharmacogenomics in oncology practice","volume":"23","author":"Patel","year":"2018","journal-title":"Oncol"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.hoc.2018.01.012","article-title":"Pain syndromes and management in adult hematopoietic stem cell transplantation","volume":"32","author":"Ma","year":"2018","journal-title":"Hematol Oncol Clin N Am"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib40","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41436-018-0431-8","article-title":"CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial","volume":"21","author":"Smith","year":"2019","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib41","first-page":"117","article-title":"Clinical application of pharmacogenetics in pain management","volume":"15","author":"Smith","year":"2018","journal-title":"M\u00e9d"},{"key":"10.1016\/j.beha.2023.101470_bib42","unstructured":"Codeine [package insert], Food and Drug Administration."},{"key":"10.1016\/j.beha.2023.101470_bib43","unstructured":"Tramadol [package insert], Food and Drug Administration."},{"issue":"11","key":"10.1016\/j.beha.2023.101470_bib44","doi-asserted-by":"crossref","first-page":"e2042","DOI":"10.1002\/onco.13953","article-title":"Impact of CYP2D6 pharmacogenomic status on pain control among opioid-treated oncology patients","volume":"26","author":"Reizine","year":"2021","journal-title":"Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41436-020-01050-4","article-title":"A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management","volume":"23","author":"Thomas","year":"2021","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/ALN.0000000000000405","article-title":"OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis","volume":"121","author":"Hwang","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.beha.2023.101470_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112060","article-title":"Reviewing pharmacogenetics to advance precision medicine for opioids","volume":"142","author":"Magarbeh","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1\u20132","key":"10.1016\/j.beha.2023.101470_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pain.2006.10.023","article-title":"Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene","volume":"130","author":"Reyes-Gibby","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.beha.2023.101470_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front Genet"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.psym.2019.02.004","article-title":"Psychological considerations in hematopoietic stem cell transplantation","volume":"60","author":"Amonoo","year":"2019","journal-title":"Psychosomatics"},{"issue":"11","key":"10.1016\/j.beha.2023.101470_bib53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatr"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","article-title":"CYP2C19 variation and citalopram response","volume":"21","author":"Mrazek","year":"2011","journal-title":"Pharmacogenetics Genom"},{"issue":"5","key":"10.1016\/j.beha.2023.101470_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"175","author":"Jukic","year":"2018","journal-title":"Am J Psychiatr"},{"issue":"5","key":"10.1016\/j.beha.2023.101470_bib56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.12938","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers","volume":"122","author":"Saiz-Rodriguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.beha.2023.101470_bib57","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","article-title":"Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients","volume":"64","author":"Rudberg","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib59","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/FTD.0b013e31817d6f5d","article-title":"CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response","volume":"30","author":"Gex-Fabry","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13651500902903016","article-title":"Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms","volume":"13","author":"Van Nieuwerburgh","year":"2009","journal-title":"Int J Psychiatr Clin Pract"},{"issue":"2","key":"10.1016\/j.beha.2023.101470_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41397-020-00197-2","article-title":"Associations between the 1438A\/G, 102T\/C, and rs7997012G\/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis","volume":"21","author":"Wan","year":"2021","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"10.1016\/j.beha.2023.101470_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11121334","article-title":"Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis","volume":"11","author":"Stein","year":"2021","journal-title":"J Personalized Med"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib65","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib66","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41409-021-01281-2","article-title":"Palliative care for patients undergoing stem cell transplant: intervention components and supportive care measures","volume":"56","author":"Nelson","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2023.101470_bib67","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1200\/JCO.2002.09.064","article-title":"Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes","volume":"20","author":"Kaiser","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib68","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000542-200503000-00011","article-title":"The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?","volume":"102","author":"Candiotti","year":"2005","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.beha.2023.101470_bib70","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00228-012-1252-3","article-title":"CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers","volume":"68","author":"Gawronska-Szklarz","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib71","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/jac\/dkw118","article-title":"Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial","volume":"71","author":"Hong","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib73","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41409-022-01641-6","article-title":"Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation","volume":"57","author":"Seydoux","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2023.101470_bib74","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib75","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bbmt.2010.12.708","article-title":"Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2023.101470_bib76","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101470_bib77","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00008571-200111000-00004","article-title":"Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression","volume":"11","author":"Coles","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.beha.2023.101470_bib78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3324\/haematol.2013.089888","article-title":"Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation","volume":"99","author":"Bonifazi","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bcpt.13185","article-title":"Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: a meta-analysis","volume":"124","author":"Kim","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.beha.2023.101470_bib80","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/FPC.0000000000000007","article-title":"Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients","volume":"23","author":"Ten Brink","year":"2013","journal-title":"Pharmacogenetics Genom"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2013.38","article-title":"The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"Uppugunduri","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.beha.2023.101470_bib83","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/bcp.14031","article-title":"The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes","volume":"85","author":"Helsby","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.tpj.6500330","article-title":"Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19","volume":"5","author":"Timm","year":"2005","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"10.1016\/j.beha.2023.101470_bib85","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jcph.878","article-title":"Cytochrome P450 genetic variations can predict mRNA expression, cyclophosphamide 4-hydroxylation, and treatment outcomes in Chinese patients with non-hodgkin's lymphoma","volume":"57","author":"Shu","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.beha.2023.101470_bib86","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","volume":"55","author":"Veal","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib87","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","article-title":"Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenetics Genom"},{"issue":"26","key":"10.1016\/j.beha.2023.101470_bib88","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2013-07-516666","article-title":"CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia","volume":"122","author":"Johnson","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101470_bib89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia","volume":"23","author":"Rocha","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2023.101470_bib90","first-page":"3435","article-title":"Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis","volume":"9","author":"Hohaus","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2023.101470_bib91","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1158\/1078-0432.CCR-04-1250","article-title":"Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma","volume":"11","author":"Hohaus","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2023.101470_bib92","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2003-02-0444","article-title":"Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma","volume":"102","author":"Dasgupta","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101470_bib93","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood.V95.4.1222.004k20_1222_1228","article-title":"Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study","volume":"95","author":"Stanulla","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2023.101470_bib94","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","article-title":"Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenetics Genom"},{"key":"10.1016\/j.beha.2023.101470_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106391","article-title":"Pharmacogenomics-guided supportive oncology: a tale of two trials","volume":"105","author":"Patel","year":"2021","journal-title":"Contemp Clin Trials"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:54Z","timestamp":1761498534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1521692623000312"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101470","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101470"}}